FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1
FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022
https://finance.yahoo.com/news/freeline-announces-fda-clearance-investigational-120000440.html
Licenses targeted interventional radiotherapeutics platform
Worldwide exclusive rights obtained for patents and next-generation technology to deliver targeted, precision radiotherapeutics for solid organ cancers
Initial IND submission for treatment of liver cancer planned in 2022
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,155,547) to Alterity.
The composition of matter patent, entitled "Compounds for and Methods of Treating Diseases", underwent prioritized examination by the USPTO. The patent covers more than 80 novel compounds and secures exclusivity for a new class of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.
"We continue to identify new drug candidates to expand our portfolio and protect our therapeutic approach to address neurodegeneration," said David Stamler, M.D., Chief Executive Officer, Alterity. "With the granting of this patent and another composition of matter patent last year, we are establishing a strong foundation as a leader in targeting iron for potential disease modifying therapy for important neurodegenerative diseases such as Parkinson's and Alzheimer's."
The patent will provide Alterity with exclusivity over the compounds claimed in the patent through 2041, thus providing a strong basis for drug development and commercialization in major neurodegenerative diseases.
https://finance.yahoo.com/news/alterity-therapeutics-granted-us-patent-123000762.html
Agreement will Bring Alnylam’s Proprietary siRNA Technology to Bear on Liver Target Identified by Novartis Researchers –
– Alnylam and Novartis have Agreed to Collaborate on Discovery and Development of siRNA-based Targeted Therapy to Restore Functional Liver Cells in Patients with End-Stage Liver Diseases --
– Collaboration Aims to Develop Liver-Targeted Therapy as a Potential Alternative to Transplantation for Patients Experiencing Liver Failure –
https://finance.yahoo.com/news/alnylam-announces-collaboration-novartis-explore-123000768.html
Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
– Expecting Key Data Readouts for Oral Fadraciclib in 2022 –
– Planning to Launch Two Registration-Directed Studies for Differentiated Oral PLK1 Inhibitor, CYC140 –
https://finance.yahoo.com/news/cyclacel-pharmaceuticals-reviews-2021-achievements-120000726.html
Medical device maker Stryker Corp said on Thursday it had agreed to acquire digital care platform Vocera Communications Inc for about $2.97 billion.
Vocera shares were up nearly 27% at $78.63 before the bell, just shy of the offer price of $79.25 per share.
Founded in 2000, Vocera caters to nearly 1,900 hospitals, allowing healthcare workers to communicate and collaborate with co-workers and engage with patients and their families.
The deal is expected to close in the first quarter of this year and is estimated to have a neutral impact on net earnings per diluted share in 2022, Stryker said.
https://finance.yahoo.com/news/medical-device-maker-stryker-buy-132307124.html
